Selective resistance to different glucocorticoids in severe autoimmune disorders

Clinical Immunology

Volumn 134, Issue 3, 2010, Pages 313-319

  Drigo, Ilenia ^a,b   Piscianz, Elisa ^b   Valencic, Erica ^a   De Iudicibus, Sara ^a,b   Tommasini, Alberto ^a,b   Ventura, Alessandro ^a,b   Decorti, Giuliana ^b  

^a INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Betamethasone; Glucocorticoids; Inflammatory diseases; Methylprednisolone; Multidrug Resistance related Protein 1; P glycoprotein; Resistance

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; AZATHIOPRINE; BETAMETHASONE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; FLUDARABINE; GLUCOCORTICOID; GLYCOPROTEIN P; IMMUNOGLOBULIN; INFLIXIMAB; METHYLPREDNISOLONE; MULTIDRUG RESISTANCE PROTEIN 1; PREDNISONE; RAPAMYCIN; RHODAMINE 123; RITUXIMAB; TACROLIMUS; THALIDOMIDE; TRITIUM;

APHTHOUS ULCER; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; COLON RESECTION; CONCENTRATION RESPONSE; CROHN DISEASE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; INFANT; LYMPHOCYTE; MALE; NEWBORN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AUTOIMMUNE DISEASES; BETAMETHASONE; CD4-POSITIVE T-LYMPHOCYTES; CHILD; DNA; DRUG RESISTANCE; FEMALE; FLOW CYTOMETRY; FORMAZANS; GLUCOCORTICOIDS; HUMANS; INFANT; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; METHYLPREDNISOLONE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; POLYMERASE CHAIN REACTION; PREDNISOLONE; TETRAZOLIUM SALTS; YOUNG ADULT;

EID: 76049103271     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2009.11.005     Document Type: Article

References (43)

1. Gross K.L., Lu N.Z., and Cidlowski J.A. Molecular mechanisms regulating glucocorticoid sensitivity and resistance. Mol. Cell. Endocrinol. 300 (2009) 7-16
2. van Rossum E.F., and Lamberts S.W. Glucocorticoid resistance syndrome: a diagnostic and therapeutic approach. Best Pract. Res. Clin. Endocrinol. Metab. 20 (2006) 611-626
3. Kobayashi I., Kawamura N., and Okano M. A long-term survivor with the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. N. Engl. J. Med. 345 (2001) 999-1000
4. Kobayashi I., Nakanishi M., Okano M., Sakiyama Y., and Matsumoto S. Combination therapy with tacrolimus and betamethasone for a patient with X-linked auto-immune enteropathy. Eur. J. Pediatr. 154 (1995) 594-595
5. Taddio A., Faleschini E., Valencic E., Granzotto M., Tommasini A., Lepore L., Andolina M., Barbi E., and Ventura A. Medium-term survival without haematopoietic stem cell transplantation in a case of IPEX: insights into nutritional and immunosuppressive therapy. Eur. J. Pediatr. 166 (2007) 1195-1197
6. Webster J.I., and Carlstedt-Duke J. Involvement of multidrug resistance proteins (MDR) in the modulation of glucocorticoid response. J. Steroid Biochem. Mol. Biol. 82 (2002) 277-288
7. Choudhuri S., and Klaassen C.D. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int. J. Toxicol. 25 (2006) 231-259
8. Ho R.H., and Kim R.B. Transporters and drug therapy: implications for drug disposition and disease. Clin. Pharmacol. Ther. 78 (2005) 260-277
9. Moon Y.J., Zhang S., and Morris M.E. Real-time quantitative polymerase chain reaction for BCRP, MDR1, and MRP1 mRNA levels in lymphocytes and monocytes. Acta Haematol. 118 (2007) 169-175
10. Meijer O.C., deLange E.C.M., Breimer D.D., deBoer A.G., Workel J.O., and deKloet E.R. Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P-glycoprotein knockout mice. Endocrinology 139 (1998) 1789-1793
11. Karssen A.M., Meijer O.C., van der Sandt I.C., Lucassen P.J., de Lange E.C., de Boer A.G., and de Kloet E.R. Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain. Endocrinology 142 (2001) 2686-2694
12. Karssen A.M., Meijer O.C., vanderSandt I.C.J., DeBoer A.G., DeLange E.C.M., and DeKloet E.R. The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone. J. Endocrinol. 175 (2002) 251-260
13. Nakayama A., Eguchi O., Hatakeyama M., Saitoh H., and Takada M. Different absorption behaviors among steroid hormones due to possible interaction with P-glycoprotein in the rat small intestine. Biol. Pharm. Bull. 22 (1999) 535-538
14. Gruol D.J., and Bourgeois S. Chemosensitizing steroids: glucocorticoid receptor agonists capable of inhibiting P-glycoprotein function. Cancer Res. 57 (1997) 720-727
15. Ueda K., Okamura N., Hirai M., Tanigawara Y., Saeki T., Kioka N., Komano T., and Hori R. Human P-glycoprotein transports cortisol, aldosterone and dexamethasone, but not progesterone. J. Biol. Chem. 267 (1992) 24248-24252
16. Yates C.R., Chang C., Kearbey J.D., Yasuda K., Schuetz E.G., Miller D.D., Dalton J.T., and Swaan P.W. Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm. Res. 20 (2003) 1794-1803
17. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 (1983) 55-63
18. Koper J.W., Stolk R.P., de Lange P., Huizenga N.A., Molijn G.J., Pols H.A., Grobbee D.E., Karl M., de Jong F.H., Brinkmann A.O., and Lamberts S.W. Lack of association between five polymorphisms in the human glucocorticoid receptor gene and glucocorticoid resistance. Hum. Genet. 99 (1997) 663-668
19. Ruiz M., Lind U., Gafvels M., Eggertsen G., Carlstedt-Duke J., Nilsson L., Holtmann M., Stierna P., Wikstrom A.C., and Werner S. Characterization of two novel mutations in the glucocorticoid receptor gene in patients with primary cortisol resistance. Clin. Endocrinol. 55 (2001) 363-371
20. Nagano M., Nakamura T., Niimi S., Fujino T., Nishimura T., Murayama N., Ishida S., Ozawa S., Saito Y., and Sawada J. Substitution of arginine for cysteine 643 of the glucocorticoid receptor reduces its steroid-binding affinity and transcriptional activity. Cancer Lett. 181 (2002) 109-114
21. Hearing S.D., Norman M., Probert C.S., Haslam N., and Dayan C.M. Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes. Gut 45 (1999) 382-388
22. Gross S.R., Aronow L., and Pratt W.B. The active transport of cortisol by mouse fibroblasts growing in vitro. Biochem. Biophys. Res. Commun. 32 (1968) 66-72
23. Farrell R.J., and Kelleher D. Glucocorticoid resistance in inflammatory bowel disease. J. Endocrinol. 178 (2003) 339-346
24. Sakamoto S., Homma S., Kawabat M., Kono T., Motoi N., and Yoshimur K. A case of corticosteroid-resistant nonspecific interstitial pneumonia associated with dermatomyositis successfully treated with cyclosporin A. Nihon Kokyuki Gakkai Zasshi 43 (2005) 171-178
25. Barnes P.J., and Adcock I.M. Glucocorticoid resistance in inflammatory diseases. Lancet 373 (2009) 1905-1917
26. HirschErnst K.I., Ziemann C., Foth H., Kozian D., SchmitzSalue C., and Kahl G.F. Induction of mdr1b mRNA and P-glycoprotein expression by tumor necrosis factor alpha in primary rat hepatocyte cultures. J. Cell. Physiol. 176 (1998) 506-515
27. Henmi K., Yoshida M., Yoshikawa N., and Hirano T. P-glycoprotein functions in peripheral-blood CD4+ cells of patients with systemic lupus erythematosus. Biol. Pharm. Bull. 31 (2008) 873-878
28. Lee R.W., Creed T.J., Schewitz L.P., Newcomb P.V., Nicholson L.B., Dick A.D., and Dayan C.M. CD4+CD25(int) T cells in inflammatory diseases refractory to treatment with glucocorticoids. J. Immunol. 179 (2007) 7941-7948
29. Coon J.S., Wang Y.Z., Bines S.D., Markham P.N., Chong A.S., and Gebel H.M. Multidrug resistance activity in human lymphocytes. Hum. Immunol. 32 (1991) 134-140
30. Farrell R.J., Menconi M.J., Keates A.C., and Kelly C.P. P-glycoprotein-170 inhibition significantly reduces cortisol and ciclosporin efflux from human intestinal epithelial cells and T lymphocytes. Aliment. Pharm. Ther. 16 (2002) 1021-1031
31. Maillefert J.F., Maynadie M., Tebib J.G., Aho S., Walker P., Chatard C., Dulieu V., Bouvier M., Carli P.M., and Tavernier C. Expression of the multidrug resistance glycoprotein 170 in the peripheral blood lymphocytes of rheumatoid arthritis patients. The percentage of lymphocytes expressing glycoprotein 170 is increased in patients treated with prednisolone. Br. J. Rheumatol. 35 (1996) 430-435
32. Barnes K.M., Dickstein B., Cutler Jr. G.B., Fojo T., and Bates S.E. Steroid treatment, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells. Biochemistry 35 (1996) 4820-4827
33. van Kalken C.K., Broxterman H.J., Pinedo H.M., Feller N., Dekker H., Lankelma J., and Giaccone G. Cortisol is transported by the multidrug resistance gene product P-glycoprotein. Br. J. Cancer 67 (1993) 284-289
34. Gruol D.J., Vo Q.D., and Zee M.C. Profound differences in the transport of steroids by two mouse beta-glycoproteins. Biochem. Pharmacol. 58 (1999) 1191-1199
35. Farrell R.J., Murphy A., Long A., Donnelly S., Cherikuri A., OToole D., Mahmud N., Keeling P.W.N., Weir D.G., and Kelleher D. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 118 (2000) 279-288
36. Tsujimura S., Saito K., Nawata M., Nakayamada S., and Tanaka Y. Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis. Ann. Rheum. Dis. 67 (2008) 380-388
37. Bourgeois S., Gruol D.J., Newby R.F., and Rajah F.M. Expression of an mdr gene is associated with a new form of resistance to dexamethasone-induced apoptosis. Mol. Endocrinol. 7 (1993) 840-851
38. Oka A., Oda M., Saitoh H., Nakayama A., Takada M., and Aungst B.J. Secretory transport of methylprednisolone possibly mediated by P-glycoprotein in Caco-2 cells. Biol. Pharm. Bull. 25 (2002) 393-396
39. McClean S., and Hill B.T. Evidence of post-translational regulation of P-glycoprotein associated with the expression of a distinctive multiple drug-resistant phenotype in Chinese hamster ovary cells. Eur. J. Cancer 29A (1993) 2243-2248
40. Kobayashi H., and Takemura Y. Quantitative analysis of multidrug resistance phenotype in hematological malignancies. Rinsho Byori 46 (1998) 380-390
41. Tsujimura S., Saito K., Nakayamada S., Nakano K., Tsukada J., Kohno K., and Tanaka Y. Transcriptional regulation of multidrug resistance-1 gene by interleukin-2 in lymphocytes. Genes Cells 9 (2004) 1265-1273
42. Tsujimura S., Saito K., Kohno K., and Tanaka Y. Fragmented hyaluronan induces transcriptional up-regulation of the multidrug resistance-1 gene in CD4+ T cells. J. Biol. Chem. 281 (2006) 38089-38097
43. Pavek P., Merino G., Wagenaar E., Bolscher E., Novotna M., Jonker J.W., and Schinkel A.H. Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine. J. Pharmacol. Exp. Ther. 312 (2005) 144-152